Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead

Five big global health wins in 2025 that will save millions of lives

From HIV to TB, scientists and doctors made breakthroughs in treatment and prevention of some of the world’s deadliest diseases

The Guardian - UK

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

MarketBeat

HIV ‘vaccine’ will reach just 7% of people needed to end Aids pandemic

The figure comes as the UN reports a ‘devastating’ collapse of HIV prevention services around the world

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Benzinga

Eswatini is the first African country to get twice-yearly HIV prevention shot

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global health officials call a game-changer

The Independent UK

3 Cash-Rich Stocks With High Growth Potential Right Now

Discover three high free cash flow yield stocks—Salesforce, Applied Materials, and Gilead Sciences—offering stability and long-term growth potential

MarketBeat

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

Barchart

South Africa's health minister hails new HIV prevention jab but warns of limited supply

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease

The Independent UK

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Benzinga

Landmark deals for cheaper ‘pandemic-ending’ HIV jab hailed as ‘huge’ step forward

Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – but aid cuts still risk its rollout

The Independent UK

Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic

Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say

The Guardian - UK

Cheaper HIV prevention jab to roll out in lower income countries in 2027

The twice-yearly drug has been hailed as a medical breakthrough that could change the course of the HIV epidemic.

Euronews

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

The US will buy 2 million doses of an HIV prevention drug for low-income countries

The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028

Barchart

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

Euronews

EU approves new twice-yearly HIV prevention jab

The new treatment option comes amid a rise in HIV cases in parts of Europe.

Benzinga

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths

This biotech giant has hidden strengths that could unlock long-term upside.

Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

The Independent UK

EU regulator approves injectable HIV drug that experts say could help stop transmission

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV

Euronews

EU regulators greenlight twice-yearly HIV injection, hailed as medical breakthrough

The drug is expected to be formally approved by the European Commission this year.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.